ClinicalTrials.gg
RecruitingNCT07436312U-TRANSUpdated May 8, 2026

Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer

An interventional study of educational workshop on nutrition + additional intervention on UPF tool and how to use it in Breast Cancer, Pancreas Cancer and Colon Cancer, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Breast Neoplasms by Gustave Roussy, Cancer Campus, Grand Paris — 8 open to participants now, 9 under way, 3 of them phase 3. Breast Neoplasms · Gustave Roussy, Cancer Campus, Grand Paris.

Planned enrollment
7th of 20
170 · median 140
Started
2026
with 2 others
No phase
4 of 20
1 open now
Registered
19th of 20
by date

Among the 20 studies in Breast Neoplasms by Gustave Roussy, Cancer Campus, Grand Paris, this one is the 7th largest by planned enrollment, is one of 3 that started in 2026, is one of 4 with no phase, and was the 19th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 20 studies in Breast Neoplasms by Gustave Roussy, Cancer Campus, Grand Paris are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Breast Neoplasms by Gustave Roussy, Cancer Campus, Grand Paris, or all of them as a file.
02

Study summary

The U-TRANS study was initiated by Gustave Roussy, which is its sponsor*. It is part of the Interception Program and aims to reduce the consumption of ultra-processed foods in order to improve the overall quality of the diet among people at high risk of cancer (WCRF score ≤ 5, corresponding to low adherence to nutritional cancer prevention recommendations: eating a diet rich in whole grains, vegetables, fruit and fibre, and limiting ultra-processed foods, red meat, processed meats, sugary drinks and alcohol). It assesses the impact of a digital intervention (based on the use of the Open Food Facts app) as a complement to the nutritional education provided by the Interception program.

Read the detailed description

The consumption of ultra-processed foods (UPFs) has increased in our diet over the past 50 years. Their consumption is associated with poor nutritional profiles. In recent years, it has been associated with numerous pathologies, including obesity, diabetes, cardiovascular disease and, more recently, cancer.

An improvement in people's nutritional profiles (measured in particular by the internationally recognized WCRF score) is associated with a lower risk of cancer, whether in the general population or in people at high risk of cancer. However, changing dietary habits is not easy, especially over the long term, due to its cultural, economic and social components.

PO: To demonstrate whether an intervention aiming to decrease the consumption of UPF improves the global diet quality of individuals at high risk of different cancers.

SO.1 To compare the magnitude of change in UPF consumption between the two arms (simple education versus intervention with the Open Food Facts application), using a validated food frequency questionnaire designed to capture UPF exposure (Canadian questionnaire that will be adapted to the French population).

SO.2 To describe the change in frequency of use of the Open Food Facts application from baseline to 12 weeks in the intervention arm.

SO.3 To assess the determinants of changes in UPF consumption behaviors before and after the intervention.

SO.4 To identify factors associated with a greater improvement in global diet quality, a larger decrease in UPF consumption, and the observance of the UPF consumption including relevant clinical and demographic characteristics.

EO.1 To evaluate participants' attitudes towards UPF and the Open Food Facts application and investigate the relationship between these attitudes, food literacy, and UPF consumption behaviors.

03

Conditions studied

  • Breast Cancer
  • Pancreas Cancer
  • Colon Cancer
  • Lynch Syndrome
  • Germline BRCA1 Gene Mutation
  • Germline BRCA2 Gene Mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > 18 years,
  2. Individuals at increased risk of different cancers as defined within the Interception program,
  3. With a baseline WCRF score ≤ 5 at entry in the Interception program,
  4. Agreeing to participate and who have given their written agreement for the study,
  5. Agreeing to fill in the questionnaires on the dedicated platform for the duration of the study,
  6. Participant have and accept to use their smartphone,
  7. All participants must understand spoken and written French language

Exclusion criteria

Exclusion Criteria:

  1. Psychiatric disorders or cognitive impairments precluding participation,
  2. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Intervention group

    The patients will receive an educational workshop on nutrition and an additional intervention on UPF tool and how to use it

    Behavioral: educational workshop on nutrition + additional intervention on UPF tool and how to use it

  • No intervention
    Control group

    The patients will only receive en educational workshop on nutrition

Interventions

  • Behavioraleducational workshop on nutrition + additional intervention on UPF tool and how to use it

    Participants with WCRF score at baseline ≤ 5 will be randomized at 1:1 ratio between intervention group (educational workshop on nutrition + additional intervention on UPF tool and how to use it) and control group (educational workshop on nutrition only). Impact will be assessed at 12 weeks with the WCRF questionnaire.

06

What researchers measure

Primary outcomes

  1. Proportion (%) of participants with at least 1-point improvement in the WCRF score

    The primary endpoint is the proportion (%) of participants with at least 1-point improvement in the WCRF score (ranging from 0 to 7 , the higher the healthier) at 12 weeks compared to baseline, in the intervention arm versus the control arm.

    Time frame: Week 12

Secondary outcomes

  1. Consumption of UPF

    The difference in the decrease of the UPF consumption score (ranging from 0 to 6, the lower - the lower consumption) between the two arms at 12 weeks (see SO.1)

    Time frame: week 12

  2. Difference in the score of Open Food Facts application use

    The difference in the increase of the ordinal scale score (ranging from 0 to 6, the higher the healthier) of Open Food Facts application use between the two arms at 12 weeks (see SO.2)

    Time frame: week 12

  3. Difference of median for each behavioral determinants

    The difference in the evolution of the 10-point Likert scale between the two arms at 12 weeks for each behavioral determinants (Capability, Opportunity, and Motivation) (see SO.3)

    Time frame: week 12

  4. Association between the difference in UPF consumption score

    The association between the difference in UPF consumption score between baseline and 12 weeks and behavioral determinants (see SO.3)

    Time frame: week 12

  5. factors associated

    The factors associated with the difference between baseline and 12 weeks (1) in the WCRF score, (2) in the UPF consumption score, and (3) in the observance of the UPF consumption, as measured by the 4th question of the questionnaire preliminary to the UPF questionnaire (see SO.4)

    Time frame: week 12

Other outcomes

  1. Qualitative assessments of participants' interview

    Qualitative assessments of participants' interview

    Time frame: week 36

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Sep 2027, 16 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 16 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Feb 27, 2026
StartActual
May 4, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Mar 2028
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07436312
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
May 4, 2026
Primary completion
Sep 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
May 8, 2026

Study contacts

Bruno Raynard, MD
Contact
bruno.raynard@gustaveroussy.fr
+33 (0) 1 42 11 42 11
Adeline Salasc, Pharm D
Contact
adeline.salasc@gustaveroussy.fr
+33 (0) 1 42 11 42 11
Bruno Raynard, MD
study chair · Gustave Roussy, Villejuif, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion